Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Ophthalmology

Why Does ROP Need Long-Term Follow-Up After Anti-VEGF?

At a Glance

After anti-VEGF treatment for retinopathy of prematurity, abnormal blood vessels may return after the medicine wears off if the retina's normal blood vessels are still developing. Regular dilated eye exams are essential because reactivation can be silent and may threaten vision.

Your baby needs frequent, long-term follow-up eye exams after receiving an anti-VEGF (anti-vascular endothelial growth factor) injection because the medication’s effect is temporary [1]. While the injection quickly suppresses the abnormal, damaging blood vessels, the medication’s protection gradually decreases [1]. If your baby’s normal retinal blood vessels have not finished growing by the time the medication wears off, the abnormal vessels can start growing again—a process called late reactivation [1]. Missing follow-up appointments means this reactivation could go unnoticed, which can sometimes progress rapidly to retinal detachment and permanent vision loss if left untreated [1][2][3].

How Anti-VEGF Medication Works (and Wears Off)

When a baby gets an anti-VEGF injection (such as bevacizumab, ranibizumab, or aflibercept), the medicine acts like a pause button on Retinopathy of Prematurity (ROP). It blocks VEGF, a chemical signal in the eye that causes abnormal, leaky blood vessels to grow [4].

However, this suppression is not permanent. The medication’s effect gradually decreases, at different rates depending on the specific drug, the dose, and the baby [1][4]. The doctor cannot give a guaranteed “wear-off” date, which is why regular eye examinations are needed [1].

During this “pause,” the goal is for the baby’s normal blood vessels to continue growing outward toward the edges of the retina (a process called vascularization). This normal growth is slow and can take many months to complete [5].

The Risk of Late Reactivation

If the anti-VEGF medication wears off before the normal blood vessels have reached the outer edges of the retina, the baby is left with persistent avascular retina—areas of the peripheral retina that do not have a blood supply [1][6]. This lack of blood supply can increase the risk of the eye restarting the disease process, leading to late reactivation of ROP [1].

Late reactivation is dangerous because it is often “silent”—it can happen without any outward signs or symptoms that you would notice at home. It most commonly occurs weeks or months after the initial injection, and in rare cases, even years later [7][8][9]. The risk is highest while significant areas of the retina remain without blood vessels [1].

If the abnormal blood vessels return, they can create scar tissue that pulls on the retina. A retinal detachment occurs when the light-sensitive retina is pulled away from its normal position at the back of the eye [1][6].

Why You Must Not Miss Appointments

Because late reactivation can happen long after you leave the Neonatal Intensive Care Unit (NICU), keeping every outpatient eye appointment is absolutely critical to protecting your baby’s vision.

  • Early detection saves sight: The eye doctor needs to look closely at the edges of the retina to see if normal blood vessels are still growing or if abnormal vessels are returning.
  • Rapid progression: If ROP reactivates, it can sometimes progress to a retinal detachment [10][2]. Prompt detection allows the doctor to treat the eye before severe damage occurs [1].
  • What to do if you miss a visit: If your baby is sick or you cannot make an appointment, do not wait for the next scheduled visit or for symptoms to appear. Call the eye clinic as soon as possible to get a replacement appointment. Missing one visit does not mean blindness is inevitable, but the clinic needs to determine how urgently your baby must be seen based on their specific retinal findings.

What Happens During Follow-Up Visits?

At these appointments, the ophthalmologist will use eye drops to dilate your baby’s pupils. This allows them to look deep into the back of the eye and check the peripheral edges of the retina. They will assess how far the normal blood vessels have grown and look for any signs of returning abnormal vessels, scar tissue, or traction.

The schedule is highly individualized. Visits may be scheduled very close together at first (e.g., every 1 to 2 weeks), and then gradually spread out as the retina stabilizes and matures.

When Do the Appointments Stop?

Your baby’s doctor will not release you from ROP-specific follow-up care simply because the initial disease has improved [1][11]. The frequent ROP checks generally continue until the ophthalmologist confirms that the retina has safely stabilized. This usually happens in one of two ways:

  1. Complete vascularization: The doctor confirms that the normal blood vessels have completely finished growing to the very edges of the retina [1].
  2. Laser treatment: If the normal blood vessels stop growing and leave permanent bare areas, the doctor may selectively use laser therapy to treat those areas and reduce the risk of future reactivation [1][11]. However, laser is not an automatic endpoint. If your baby receives laser treatment, they will still need follow-up exams to ensure the eye has healed and stabilized.

Does this mean lifelong frequent appointments?

No. The urgent, frequent ROP checks will eventually space out or stop once the ROP specialist determines the retina is stable. However, children born prematurely—especially those who needed treatment for ROP—commonly need ongoing, routine childhood eye care. They are at higher risk for issues like refractive errors (needing glasses), strabismus (crossed eyes), and amblyopia (lazy eye). Your eye team will transition you to a standard pediatric eye care schedule when the time is right.

Common questions in this guide

Why does my baby need eye exams after an anti-VEGF injection for ROP?
The medicine suppresses abnormal blood vessel growth, but its effect is temporary. If normal blood vessels have not finished growing when the medicine wears off, ROP can return, sometimes without any signs you can see at home.
Can ROP come back after anti-VEGF treatment?
Yes. Late reactivation can occur weeks or months after treatment and, rarely, much later if areas of the retina still lack normal blood vessels. Without prompt treatment, returning abnormal vessels can pull on the retina and cause retinal detachment.
How long will my baby need follow-up after ROP treatment?
There is no single schedule or guaranteed stopping date because the timing depends on how the retina develops. Follow-up usually continues until the ophthalmologist confirms complete blood-vessel growth or that the retina is stable after any needed laser treatment; visits then become less frequent, although routine childhood eye care remains important.
What happens during a follow-up visit for ROP?
The ophthalmologist will usually dilate your baby's pupils and examine the edges of the retina. They check how far normal blood vessels have grown and look for returning abnormal vessels, scar tissue, or pulling on the retina. Visits may be every one to two weeks at first and then spread out as the eye stabilizes.
What should I do if we miss an ROP follow-up appointment?
Call the eye clinic as soon as possible to arrange a replacement appointment, rather than waiting for the next visit or for symptoms. Missing one appointment does not mean blindness is inevitable, but the clinic needs to decide how urgently your baby should be examined.
Does laser treatment mean my baby no longer needs ROP follow-up?
No. Laser treatment may reduce the risk from areas where normal blood vessels stopped growing, but the eye still needs follow-up while it heals and stabilizes. The ophthalmologist will determine when ROP-specific monitoring can be reduced or ended.

Get notified when new evidence is published on Retinopathy of prematurity.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Reactivation of retinopathy of prematurity after anti-VEGF treatment: a review.

    Kumawat D, Kandasamy S, Chandra P

    The British journal of ophthalmology 2025; doi:10.1136/bjo-2025-327597.

    PMID: 40889820
  2. 2

    Characteristics of Eyes Developing Retinal Detachment After Anti-vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.

    Kondo C, Iwahashi C, Utamura S, et al.

    Frontiers in pediatrics 2022; (10()):785292 doi:10.3389/fped.2022.785292.

    PMID: 35463897
  3. 3

    Retinopathy of prematurity: a review of epidemiology and current treatment strategies.

    Hong EH, Shin YU, Cho H

    Clinical and experimental pediatrics 2022; (65(3)):115-126 doi:10.3345/cep.2021.00773.

    PMID: 34645255
  4. 4

    Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.

    VanderVeen DK, Melia M, Yang MB, et al.

    Ophthalmology 2017; (124(5)):619-633 doi:10.1016/j.ophtha.2016.12.025.

    PMID: 28341474
  5. 5

    The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity.

    Sukgen EA, Koçluk Y

    Arquivos brasileiros de oftalmologia 2017; (80(1)):30-34 doi:10.5935/0004-2749.20170009.

    PMID: 28380099
  6. 6

    Persistent avascular retina in retinopathy of prematurity.

    Tan TF, Tay SA, Agarwal-Sinha S, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(8)):2177-2190 doi:10.1007/s00417-025-06820-x.

    PMID: 40178600
  7. 7

    Anti-VEGF versus laser therapy for retinopathy of prematurity: a systematic review and meta-analysis focusing on recurrence patterns and retreatment needs.

    Krungkraipetch L, Krungkraipetch D, Krungkraipetch K

    International journal of retina and vitreous 2026; (12(1)):30 doi:10.1186/s40942-026-00810-9.

    PMID: 41618478
  8. 8

    [Long-term effects of anti-VEGF therapy for retinopathy of prematurity].

    Krohne TU, Müller A, Larsen PP, Holz FG

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2018; (115(6)):464-468 doi:10.1007/s00347-018-0700-6.

    PMID: 29654389
  9. 9

    Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab.

    Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, et al.

    Ophthalmic surgery, lasers & imaging retina 2017; (48(3)):255-259 doi:10.3928/23258160-20170301-10.

    PMID: 28297039
  10. 10

    PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.

    Yonekawa Y, Wu WC, Nitulescu CE, et al.

    Retina (Philadelphia, Pa.) 2018; (38(6)):1079-1083 doi:10.1097/IAE.0000000000001685.

    PMID: 28471890
  11. 11

    An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity.

    Nowroozzadeh MH, Sadeghi E, Shahriari-Garaee H, et al.

    Journal of current ophthalmology 2023; (35(2)):125-134 doi:10.4103/joco.joco_38_23.

    PMID: 38250486

This page explains why babies treated for ROP need ongoing eye examinations for informational purposes only and does not replace medical advice. Follow your baby's ophthalmology team's schedule and contact the clinic promptly if an appointment must be rescheduled.